NCT07325864 Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site
| NCT ID | NCT07325864 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-12-18 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2025-12-18 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
investigate the molecular differences between primitive lung cancer and the metastatic site.
Eligibility Criteria
Inclusion Criteria: * patients aged ≥18 years fit enough to tolerate the surgical operation; * the operative risk is considered low based on respiratory reserve and cardiac assessment; * the patient has clearly expressed willingness to adhere; * availability of pathological material for tumor DNA extraction and NGS execution. Exclusion Criteria: * Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study. * Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation. * Recent or ongoing severe or clinically significant infection.
Contact & Investigator
Lorenzo Spaggiari
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT07325864 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07325864 currently recruiting?
Yes, NCT07325864 is actively recruiting participants. Contact the research team at luca.bertolaccini@ieo.it for enrollment information.
Where is the NCT07325864 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07325864 clinical trial?
NCT07325864 is sponsored by European Institute of Oncology. The principal investigator is Lorenzo Spaggiari at European Institute of Oncology. The trial plans to enroll 25 participants.